Phibro Animal Health reported double-digit third-quarter growth in revenue and adjusted earnings, driven by continued strength in its Animal Health business, while raising portions of its fiscal 2026 financial guidance.
Phibro Animal Health reported strong second-quarter results driven by rapid uptake of its MFA portfolio and continued growth in nutrition and vaccine products, prompting the company to raise its fiscal year 2026 guidance.
Phibro Animal Health has launched Restoris™, a new piezoelectric dental gel for dogs designed to promote bone growth and restore oral health in cases of periodontal disease.
Sign up for free to receive the latest veterinary news, product announcements, and industry developments.